Lantheus (NASDAQ:LNTH) Issues FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $6.65-6.70 for the period, compared to the consensus estimate of $6.66. The company issued revenue guidance of $1.51-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.650-6.700 EPS.

Analysts Set New Price Targets

LNTH has been the subject of a number of recent research reports. Leerink Partners boosted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Truist Financial restated a “buy” rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, JMP Securities dropped their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Price Performance

Shares of LNTH stock traded down $0.82 during trading hours on Friday, hitting $87.50. 1,617,957 shares of the company’s stock were exchanged, compared to its average volume of 993,185. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The firm has a 50 day moving average of $107.71 and a two-hundred day moving average of $95.52. The firm has a market cap of $6.08 billion, a P/E ratio of 14.66 and a beta of 0.51. Lantheus has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $378.73 million for the quarter, compared to the consensus estimate of $373.58 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Sell-side analysts forecast that Lantheus will post 5.99 EPS for the current year.

Insider Activity at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.10% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.